Exclusive: SK Hynix expects AI memory market to grow 30% a year to 2030 Reuters
HBM roadmaps for Micron, Samsung, and SK hynix: To HBM4 and beyond Tom’s Hardware
SK Hynix Is Reportedly Raising HBM4 Prices by a Whopping 70%, Capitalizing on a ‘Monopolized Market’ by Charging a Hefty Premium for Early Delivery Wccftech
Exclusive-SK Hynix expects AI memory market to grow 30% a year to 2030 MSN
Exclusive-SK Hynix expects AI memory market to grow 30% a year to 2030 By Reuters Investing.com
Cardiologist Dr Yaranov highlights how women experience significant heart health changes throughout their lives and reveals what they can do to protect it.
Women’s heart health goes through several changes in their lifetime. In an Instagram post shared on July 31, Dr Dmitry Yaranov, MD, cardiologist, talked about how blood pressure in women changes across decades, and what they can do to protect their hearts.
According to the cardiologist, in women, from their 20s to 60s and beyond, hormonal changes, pregnancy, and menopause can significantly impact their heart health. (Shutterstock)
Also Read | Cardiologist explains if ‘Covid vaccines’ contribute to increase in heart attacks: ‘So much nonsense like mercury…’
The cardiologist wrote, “Ladies, let’s talk about your heart. Your blood pressure isn’t one number for life — especially if you’re a woman. From your 20s to postmenopause, your heart health goes through major shifts — and most women aren’t warned until it’s too late.”
Did you know your blood pressure isn’t static throughout life?
According to the cardiologist, in women, from their 20s to 60s and beyond, hormonal changes, pregnancy, and menopause can significantly impact their heart health.
Rising numbers in their 30s
Pregnancy-related risks
Postmenopausal changes triple their odds of hypertension
“These aren’t just numbers. They’re warning signs — and chances to act early,” he warned. The cardiologist also listed significant stages in a woman’s life, and what they should know about their heart health in every chapter. Let’s find out:
In your 20s-30s: Blood pressure starts to rise, increasing the risk of heart disease earlier than you might expect.
Pregnancy: Conditions like gestational hypertension and preeclampsia not only affect pregnancy but also elevate long-term cardiovascular risks.
Menopause: The decline in estrogen levels leads to stiffer blood vessels, resulting in increased blood pressure and a higher risk of hypertension.
60s and beyond: Post-menopause, women are more likely than men to develop high blood pressure, with a prevalence of 75 percent in postmenopausal women in the US.
Why does it matter?
Per the cardiologist, “High blood pressure is a leading risk factor for heart disease and stroke in women. Regular monitoring and proactive management are crucial for maintaining heart health.”
But what can you do to manage your heart health? The doctor suggested, “Monitor your blood pressure regularly and consult with your healthcare provider to understand your risks and manage your heart health effectively.”
Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Catch every big hit, every wicket with Crick-it, a one stop destination for Live Scores, Match Stats, Quizzes, Polls & much more. Explore now!.
Catch your daily dose of Fashion, Taylor Swift, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.
Catch every big hit, every wicket with Crick-it, a one stop destination for Live Scores, Match Stats, Quizzes, Polls & much more. Explore now!.
Catch your daily dose of Fashion, Taylor Swift, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.
News / Lifestyle / Health / Cardiologist reveals women’s blood pressure changes in 20s, pregnancy, menopause, 60s; how to protect their heart
Farquhar, J., Bao, H. & Thiemens, M. Atmospheric influence of earth’s earliest sulfur cycle. Science289, 756–758 (2000).
ADS
PubMed
Google Scholar
Farquhar, J. et al. Isotopic evidence for mesoarchaean anoxia and changing atmospheric sulphur chemistry. Nature449, 706–709 (2007).
ADS
PubMed
Google Scholar
Farquhar, J., Savarino, J., Airieau, S. & Thiemens, M. H. Observation of wavelength-sensitive mass-independent sulfur isotope effects during SO2 photolysis: implications for the early atmosphere. J. Geophys. Res. Planet. 106, 32829–32839 (2001).
ADS
Google Scholar
Catling, D. C. & Zahnle, K. J. The archean atmosphere. Sci. Adv.6, eaax1420 (2020).
ADS
PubMed
PubMed Central
Google Scholar
Pavlov, A. A. & Kasting, J. F. Mass-independent fractionation of sulfur isotopes in archean sediments: strong evidence for an anoxic archean atmosphere. Astrobiology2, 27–41 (2002).
ADS
PubMed
Google Scholar
Zahnle, K. J., Claire, M. W. & Catling, D. C. The loss of mass-independent fractionation in sulfur due to a paleoproterozoic collapse of atmospheric methane. Geobiology4, 271–283 (2006).
Google Scholar
Sheldon, N. Precambrian paleosols and atmospheric CO2 levels. Precambrian Res.147, 148–155 (2006).
ADS
Google Scholar
Driese, S. G. et al. Neoarchean paleoweathering of tonalite and metabasalt: implications for reconstructions of 2.69Ga early terrestrial ecosystems and paleoatmospheric chemistry. Precambrian Res.189, 1–17 (2011).
ADS
Google Scholar
Zahnle, K. J., Gacesa, M. & Catling, D. C. Strange messenger: A new history of hydrogen on earth, as told by Xenon. Geochim. Cosmochim. Acta. 244, 56–85 (2019).
ADS
Google Scholar
Kurokawa, H., Foriel, J., Laneuville, M., Houser, C. & Usui, T. Subduction and atmospheric escape of earth’s seawater constrained by hydrogen isotopes. Earth Planet. Sci. Lett.497, 149–160 (2018).
ADS
Google Scholar
Stueeken, E. E. & Buick, R. Environmental control on microbial diversification and methane production in the mesoarchean. https://doi.org/10.1016/j.precamres.2017.11.003 (2018).
Ueno, Y., Yamada, K., Yoshida, N., Maruyama, S. & Isozaki, Y. Evidence from fluid inclusions for microbial methanogenesis in the early Archaean era. Nature440, 516–519 (2006).
ADS
PubMed
Google Scholar
KHARECHA, P., Kasting, J. & Siefert, J. A coupled atmosphere–ecosystem model of the early archean Earth. Geobiology3, 53–76 (2005).
Google Scholar
Ozaki, K., Tajika, E., Hong, P. K., Nakagawa, Y. & Reinhard, C. T. Effects of primitive photosynthesis on earth’s early climate system. Nat. Geosci.11, 55–59 (2018).
ADS
Google Scholar
Israël, G. et al. Complex organic matter in titan’s atmospheric aerosols from in situ pyrolysis and analysis. Nature438, 796–799 (2005).
ADS
PubMed
Google Scholar
Arney, G. et al. The pale orange dot: the spectrum and habitability of hazy archean Earth. Astrobiology16, 873–899 (2016).
ADS
PubMed
PubMed Central
Google Scholar
Haqq-Misra, J. D., Domagal-Goldman, S. D., Kasting, P. J. & Kasting, J. F. A revised, hazy methane greenhouse for the archean Earth. Astrobiology8, 1127–1137 (2008).
ADS
PubMed
Google Scholar
Sagan, C. & Chyba, C. The early faint sun paradox: organic shielding of ultraviolet-labile greenhouse gases. Science276, 1217–1221 (1997).
ADS
PubMed
Google Scholar
Zerkle, A. L., Claire, M. W., Domagal-Goldman, S. D., Farquhar, J. & Poulton, S. W. A bistable organic-rich atmosphere on the Neoarchaean Earth. Nat. Geosci.5, 359–363 (2012).
ADS
Google Scholar
Izon, G. et al. Multiple oscillations in Neoarchaean atmospheric chemistry. Earth Planet. Sci. Lett.431, 264–273 (2015).
ADS
Google Scholar
Thomazo, C., Nisbet, E., Grassineau, N., Peters, M. & Strauss, H. Multiple sulfur and carbon isotope composition of sediments from the Belingwe greenstone belt (Zimbabwe): A biogenic methane regulation on mass independent fractionation of sulfur during the neoarchean?? Geochim. Cosmochim. Acta. 121, 120–138 (2013).
ADS
Google Scholar
Flannery, D. et al. Spatially-resolved isotopic study of carbon trapped in ∼3.43 Ga Strelley pool formation stromatolites. Geochim Cosmochim. Acta223, (2017).
Trainer, M. G. et al. Organic haze on Titan and the early Earth. Proc. Natl. Acad. Sci. U. S. A.103, 18035–18042 (2006).
Fleury, B. et al. Influence of CO on Titan atmospheric reactivity. Icarus238, 221–229 (2014).
ADS
Google Scholar
Atkinson, R. & Arey, J. Atmospheric degradation of volatile organic compounds. Chem. Rev.103, 4605–4638 (2003).
PubMed
Google Scholar
Rudich, Y., Donahue, N. M. & Mentel, T. F. Aging of organic aerosol: bridging the gap between laboratory and field studies. Annu. Rev. Phys. Chem.58, 321–352 (2007).
ADS
PubMed
Google Scholar
Sprengnether, M., Demerjian, K. L., Donahue, N. M. & Anderson, J. G. Product analysis of the OH oxidation of isoprene and 1,3-butadiene in the presence of NO. J. Geophys. Res. Atmos.107, ACH 8-1-ACH 8–13 (2002).
Volkamer, R. et al. OH-initiated oxidation of benzene. Phys. Chem. Chem. Phys.4, 1598–1610 (2002).
Google Scholar
Brassé, C., Buch, A., Coll & Raulin, F. Low-Temperature alkaline pH hydrolysis of Oxygen-Free Titan tholins: carbonates’ impact. Astrobiology17, 8–26 (2017).
ADS
PubMed
Google Scholar
Neish, C. D., Somogyi, Á. & Smith, M. A. Titan’s primordial soup: formation of amino acids via Low-Temperature hydrolysis of Tholins. Astrobiology10, 337–347 (2010).
ADS
PubMed
Google Scholar
Khare, B. N. et al. Amino acids derived from Titan Tholins. Icarus68, 176–184 (1986).
ADS
PubMed
Google Scholar
Derenne, S. et al. New insights into the structure and chemistry of titan’s Tholins via 13 C and 15 N solid state nuclear magnetic resonance spectroscopy. Icarus221, 844–853 (2012).
ADS
Google Scholar
Gautier, T. et al. Development of HPLC-Orbitrap method for identification of N-bearing molecules in complex organic material relevant to planetary environments. Icarus275, 259–266 (2016).
ADS
Google Scholar
Morisson, M., Szopa, C., Carrasco, N., Buch, A. & Gautier, T. Titan’s organic aerosols: molecular composition and structure of laboratory analogues inferred from pyrolysis gas chromatography mass spectrometry analysis. Icarus277, 442–454 (2016).
ADS
Google Scholar
Quirico, E. et al. New experimental constraints on the composition and structure of Tholins. Icarus198, 218–231 (2008).
ADS
Google Scholar
Maillard, J. et al. Humid evolution of haze in the atmosphere of Super-Earths in the habitable zone. Astrobiology23, 723–732 (2023).
ADS
PubMed
Google Scholar
Poch, O., Coll, P., Buch, A., Ramírez, S. I. & Raulin, F. Production yields of organics of Astrobiological interest from H2O–NH3 hydrolysis of titan’s Tholins. Planet. Space Sci.61, 114–123 (2012).
ADS
Google Scholar
Jaziri, A. Y., Charnay, B., Selsis, F., Leconte, J. & Lefèvre, F. Dynamics of the great oxidation event from a 3D photochemical–climate model. Clim. Past. 18, 2421–2447 (2022).
Google Scholar
Velivetskaya, T. A., Ignatiev, A. V., Vysotskiy, S. V. & Aseeva, A. V. Ratios of sulfur isotopes (32S, 33S, 34S, and 36S) in archean rocks of karelia: evidence of microbial life and the anoxic atmosphere. Russ Geol. Geophys.65, 689–698 (2024).
Google Scholar
Archer, C. & Vance, D. Coupled Fe and S isotope evidence for archean microbial Fe(III) and sulfate reduction. Geology34, 153–156 (2006).
ADS
Google Scholar
Craddock, P. R. & Dauphas, N. Iron and carbon isotope evidence for microbial iron respiration throughout the archean. Earth Planet. Sci. Lett.303, 121–132 (2011).
ADS
Google Scholar
Schopf, J. W. The fossil record of cyanobacteria. in Ecology of Cyanobacteria II: their Diversity in Space and time (ed Whitton, B. A.) 15–36 (Springer Netherlands, Dordrecht, doi:https://doi.org/10.1007/978-94-007-3855-3_2. (2012).
Google Scholar
de Bueno, C. P., Wu, D. & Tringe, S. G. Methyl-Based methanogenesis: an ecological and genomic review. Microbiol. Mol. Biol. Rev. MMBR. 87, e00024–e00022 (2013).
Google Scholar
Blaut, M. Metabolism of methanogens. Antonie Van Leeuwenhoek. 66, 187–208 (1994).
PubMed
Google Scholar
Schauder, R. & Kröger, A. Bacterial sulphur respiration. Arch. Microbiol.159, 491–497 (1993).
Google Scholar
Ebrahiminezhad, A., Manafi, Z., Berenjian, A., Kianpour, S. & Ghasemi, Y. Iron-Reducing bacteria and iron nanostructures. J. Adv. Med. Sci. Appl. Technol.3, 9 (2017).
Google Scholar
Bonch-Osmolovskaya, E. A., Sokolova, T. G., Kostrikina, N. A. & Zavarzin, G. A. Desulfurella acetivorans gen. Nov. And sp. Nov. —a new thermophilic sulfur-reducing Eubacterium. Arch. Microbiol.153, 151–155 (1990).
Google Scholar
Straub, K. L. & Buchholz-Cleven, B. E. Geobacter Bremensis sp. Nov. And geobacter pelophilus sp. Nov., two dissimilatory ferric-iron-reducing bacteria. Int. J. Syst. Evol. Microbiol.51, 1805–1808 (2001).
PubMed
Google Scholar
Veglió, F., Passariello, B., Barbaro, M., Plescia, P. & Marabini, A. M. Drum leaching tests in iron removal from quartz using oxalic and sulphuric acids. Int. J. Min. Process.54, 183–200 (1998).
Google Scholar
Veaudor, T., Cassier-Chauvat, C. & Chauvat, F. Genomics of Urea transport and catabolism in cyanobacteria: biotechnological implications. Front. Microbiol.10, 2052 (2019).
PubMed
PubMed Central
Google Scholar
Solomon, C., Collier, J., Berg, G. & Glibert, P. Role of Urea in microbial metabolism in aquatic systems: a biochemical and molecular review. Aquat. Microb. Ecol.59, 67–88 (2010).
Google Scholar
Grettenberger, C. L. et al. A phylogenetically novel Cyanobacterium most closely related to Gloeobacter. ISME J.14, 2142–2152 (2020).
PubMed
PubMed Central
Google Scholar
Lahav, N., White, D. & Chang, S. Peptide formation in the prebiotic era: thermal condensation of Glycine in fluctuating clay environments. Science201, 67–69 (1978).
ADS
PubMed
Google Scholar
Wolf, E. T. & Toon, O. B. Fractal organic hazes provided an ultraviolet shield for early Earth. Science328, 1266–1268 (2010).
ADS
PubMed
Google Scholar
Canfield, D. E., Rosing, M. T. & Bjerrum, C. Early anaerobic metabolisms. Philos. Trans. R Soc. B Biol. Sci.361, 1819–1836 (2006).
Google Scholar
Szopa, C., Cernogora, G., Boufendi, L., Correia, J. J. & Coll, P. PAMPRE: A dusty plasma experiment for titan’s Tholins production and study. Planet. Space Sci.54, 394–404 (2006).
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Just Group PLC (LSE:JUST) reported a 34% increase in profits to 504 million, with operating earnings per share up 36%.
The company achieved record sales of 5.3 billion, driven by a 36% increase in new business sales.
The DB business completed its largest transaction to date, a 1.8 billion scheme, showcasing its strong market position.
The solvency ratio stands at a robust 204%, providing significant headroom for future growth.
The dividend was increased by 20%, reflecting confidence in the business’s future prospects.
The share price reaction was not as positive as expected despite strong financial results.
There is uncertainty regarding the impact of regulatory changes, such as the 42 million hit from Solvency UK reforms.
The company faces potential challenges in maintaining margins if credit spreads tighten further.
The market for DB transactions is expected to be more weighted towards the second half of the year, which may affect short-term growth visibility.
There are concerns about the sustainability of low new business strain, which has been consistently below target.
Q: Can you provide an update on the DB pipeline and the impact of recent transactions on your growth plans? A: (David Richardson, CEO) Our Beacon platform continues to grow, with over 300 schemes now loaded. We’ve opened up the market for larger transactions, such as our first over 1 billion deal in 2024. Our pipeline remains strong, and we expect growth to be more weighted towards the second half of the year.
Q: What factors influenced the decision to increase the dividend by 20%? A: (Mark Godson, CFO) We consider cash, earnings, and capital over the medium term. Dividends are a small part of our surplus generation, with most surplus reinvested in new business. The increase reflects confidence in the business’s long-term value.
Q: Why haven’t you set new targets after achieving your previous profit doubling goal ahead of schedule? A: (David Richardson, CEO) We’ve exceeded our target by increasing profits by 2.4 times in three years. We are confident in our ability to grow earnings at an attractive rate from this higher level, supported by our strong business franchise and market opportunities.
Q: How do you view the use of funded reinsurance given regulatory scrutiny? A: (David Richardson, CEO) We are comfortable with our risk management practices and have always engaged openly with regulators. Funded reinsurance is an option to enhance margins but not a dependency for our profitability or future expectations.
Q: Can you explain the low new business strain and whether you’re considering taking on more risk? A: (Mark Godson, CFO) Our low new business strain is due to disciplined pricing and market conditions. We focus on sustainable growth and high returns on investment. We are not looking to change our target of less than 2.5% strain, even though we’ve consistently been below it.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
HYDERABAD: Governor Sindh Kamran Khan Tessori arrived in Hyderabad today, where he addressed a press conference at a local hotel. He expressed gratitude to the journalist community for their consistent cooperation and extensive coverage on each of his visits to the city.
Speaking about the purpose of his current visit, the Governor said that today’s program is part of the 14th August Independence Day celebrations and the “Battle of Truth” Marka-e-Haq series of events.
Governor Sindh noted that just as the Governor House had hosted renowned singer Rahat Fateh Ali Khan earlier, today the people of Hyderabad will enjoy the performance of celebrated artist Ali Zafar at Bagh-e-Mustafa, Latifabad. The event will be a grand, colourful musical evening, complete with digital screens displaying the “Battle of Truth” Marka e Haq festivities, and decorations matching those at the Governor House. He congratulated the Sindh Government for the successful musical programme held earlier at Rani Bagh, calling it a vibrant part of the Independence Day celebrations.
Governor Sindh stated that whether it is musical shows like the one at Rani Bagh, today’s mega event at Bagh-e-Mustafa, or the IT courses being launched, the good days for the people of Hyderabad have already begun. Regarding IT courses, Governor Kamran Khan Tessori announced that all preparations have been completed, 1,000 computers have been purchased for the computer labs, and over 50 faculty members have been appointed.
The first phase will be launched at the university previously established by MQM, while discussions are ongoing with the Divisional Commissioner and Mayor Hyderabad for a permanent venue. Out of 50,000 students, 22,000 are already earning 600 US dollars per month through these initiatives.
Highlighting the unique features of today’s event, the Governor announced that Bagh-e-Mustafa will host a world record-breaking fireworks display lasting one hour and twenty minutes. He praised the dedication of the organizing team, who have been working day and night for the past five days to ensure flawless arrangements. Our MPAs and MNAs are making every effort to make this musical program a success. He added. Next event will be held at Pakka Qila, as we continue moving forward with the mission of the ‘Battle of Truth’, he said.
Governor Sindh also provided updates on the Hyderabad Development Package, confirming that Rs. 5 billion has already been received in the first phase through PIDCL, with another Rs. 5 billion to follow in the second phase.
Development projects have been handed over to contractors, and work will be carried out under the supervision of PIDCL, in accordance with schemes submitted by MNAs. He reiterated his commitment to fulfilling promises made to provide employment opportunities for the people of Hyderabad.
The people of Hyderabad will themselves witness how close this city is to my heart. The doors of the Governor House are always open to them. Development projects funded through MPAs’ and MNAs’ allocations will be carried out under my direct supervision, Governor Sindh assured.
Governor Sindh further announced that next week, two inactive hospitals of the international relief organisation Red Cross in Hyderabad will be made operational, with visits arranged for the Consul General. The Governor also revealed plans to invite more than seven Federal Ministers to Hyderabad’s Chambers of Commerce to discuss development projects and consult with the business community.
Governor Kamran Tessori concluded by reaffirming his mission, we are united and moving forward with full determination to work for the people of Hyderabad and Karachi. Whether it is a matter of resources, employment, or admissions in universities and colleges, any shortcomings will be eliminated. We want to uplift Hyderabad and Karachi, and we are working for the progress of our local areas, the province, and the country.
Residents in central Victoria have reported seeing a large meteor streaking across the night sky on Sunday, with some people describing an extremely bright fireball and a loud sound as the object passed overhead.
Dozens of clips and witness accounts were shared in the Facebook group Australian Meteor Reports.
Saskia Reus-Smit, from Fryerstown, posted to the group that they had seen the meteor pass “directly over my head, very low, seemed lower than a plane … close enough to see burning definition, like a volcanic rock burning orange, shades of black rock formation shadows clearly visible”.
Sign up: AU Breaking News email
Soon after, Reus-Smit experienced “a massive boom, sounded more like impact than sonic boom but could have been either. My house and the earth shook visibly.”
Terrence Dale, who lives in Eildon, wrote on Facebook he saw the meteor at 7.35pm.
“Low on the horizon and it was blue and red in colour and was extremely long in shape, it dropped from my view due to mountain range near where we live,” Dale wrote.
“I knew what it was as I’ve been reading a lot on social media of a meteor shower happening soon, I just happened to be outside on a very clear night and was looking in the right direction.”
Dale said he was left awestruck by the display.
The meteor was also captured by the Pendergast Hut cam on Mt Buller, at 7.40pm.
skip past newsletter promotion
after newsletter promotion
A screenshot from a camera on Mt Buller shows the meteor as it flew overhead. Photograph: Mt Buller
Astrophysicist and astronomer Prof Jonti Horner, from the University of Southern Queensland, confirmed it was a meteor that had lit up the sky.
“It was definitely a meteor. Because of how bright it was, we describe it as a ‘fireball’ – which just means a meteor that was brighter in the sky than the planet Venus appears,” Horner said.
“From how bright it was and the fact there was a widely heard sonic boom-rumble a few minutes after it appeared, it seems likely that fragments could have made it to the ground.”
He said to his knowledge nothing has been found yet – though this was not surprising, as meteorites are hard to find, he said.
HONG KONG, Aug. 10, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ivonescimab, a first-in-class PD-1/VEGF bispecific antibody developed by Akeso, in small cell lung cancer (SCLC). This study is designed to assess the efficacy and safety of ivonescimab as consolidation therapy in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced progression following standard concurrent chemoradiotherapy (cCRT).
AK112-311/HARMONi-9 study is the eighth registrational Phase III clinical trial for ivonescimab in lung cancer (including three international multicenter studies). The initiation of this trial further expands ivonescimab’s therapeutic coverage across key lung cancer indications and different lines of treatment. As the world’s first PD-1/VEGF bispecific antibody, ivonescimab is driving significant transformation in the overall lung cancer treatment landscape and holds the potential to fundamentally improve global lung cancer therapies.
Small cell lung cancer (SCLC) represents approximately 15% of all lung cancers and is known for its aggressive nature, early metastasis, and poor prognosis. Around 30% of patients are diagnosed at the limited stage (LS-SCLC), with over 80% being ineligible for surgical intervention. The current standard of care involves concurrent or sequential chemoradiotherapy (cCRT/sCRT), where most patients face recurrence or develop drug resistance. To date, only one PD-L1 therapy has been approved for consolidation treatment for LS-SCLC, highlighting the significant unmet clinical need of this difficult to treat cancer.
In previous studies focused on extensive-stage SCLC (ES-SCLC), ivonescimab has demonstrated its ability to prolong progression-free survival (PFS), combining the synergistic benefits of PD-1/L1 inhibitors and anti-angiogenic agents. Ivonescimab is a cornerstone in Akeso’s “IO 2.0” strategy, and Akeso has already initiated a series of Phase III and Phase II clinical trials investigating ivonescimab as a first-line treatment across multiple cancer indications. The initiation of a Phase III study of ivonescimab for LS-SCLC is another key step in extending Akeso’s “IO 2.0” approach to earlier stages of lung cancer.
Forward-Looking Statement of Akeso, Inc. This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
About Akeso Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 2 new drugs with 2 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.
For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.
Catch every big hit, every wicket with Crick-it, a one stop destination for Live Scores, Match Stats, Quizzes, Polls & much more. Explore now!.
